Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.

about

Alzheimer’s Disease, Brain Injury, and C.N.S. Nanotherapy in Humans: Sonoporation Augmenting Drug Targeting.Amsterdam Dementia Cohort: Performing Research to Optimize Care.

P2860

Q47408666-7030C23B-89C3-42ED-85B1-761BCE08CC91 Q52644592-E554EFFF-B6BF-4FCC-8468-98C3DC0AE4CA

P2860

Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.

Item

http://www.wikidata.org/entity/Q40401981

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Apolipoprotein A1 in Cerebrosp ...... sease in Non-Demented Elderly.

@en

type

Item

label

Apolipoprotein A1 in Cerebrosp ...... sease in Non-Demented Elderly.

@en

prefLabel

Apolipoprotein A1 in Cerebrosp ...... sease in Non-Demented Elderly.

@en

P1476

Apolipoprotein A1 in Cerebrosp ...... sease in Non-Demented Elderly.

@en

P2093

Argonde C Van Harten

http://www.w3.org/2001/XMLSchema#string

Femke H Bouwman

http://www.w3.org/2001/XMLSchema#string

Maartje I Kester

http://www.w3.org/2001/XMLSchema#string

Robert Veerhuis

http://www.w3.org/2001/XMLSchema#string

Rosalinde E R Slot

http://www.w3.org/2001/XMLSchema#string

Wesley Jongbloed

http://www.w3.org/2001/XMLSchema#string

P2860

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity

Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model

ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

“Mini-mental state”

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Mild cognitive impairment: clinical characterization and outcome

APOA1 polymorphism influences risk for early-onset nonfamiliar AD

P304

687-697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JAD-151068

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Philip Scheltens

Charlotte Teunissen

Wiesje van der Flier

P577

2016-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28035918

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

cerebrospinal fluid

Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.

about

P2860

P2860

Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921